Combination therapy with nivolumab and ipilimumab led to notable antitumor activity and durable response among patients with metastatic renal cell carcinoma, according to safety and efficacy results of the CheckMate 016 clinical trial.

“For this group of patients, these are very significant results,” Hans J. Hammers, MD, PhD, associate professor of internal medicine at UT Southwestern, and co-leader of the kidney cancer program at The Harold C. Simmons Compressive Cancer Center, said in a press release.